RNAi for the Treatment of Viral Hepatitis
RNAi 治疗病毒性肝炎
基本信息
- 批准号:8045679
- 负责人:
- 金额:$ 18.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-12 至 2011-03-31
- 项目状态:已结题
- 来源:
- 关键词:Alberta provinceAlgorithmsAmericanAnimal ModelAnimalsBiologicalCellsCessation of lifeDNA Polymerase IIDataEscape MutantEvaluationEvolutionExhibitsGenesGenotypeGoalsGrantHealthHepatitis BHepatitis B VaccinesHepatitis B VirusHepatitis CHepatitis C virusHepatitis VirusesHepatocyteHumanHuman Viral HepatitisIn VitroIndividualInfectionInfectious hepatitidesInterferonsLeadLengthLiverLiver FailureLuciferasesMediatingMonitorMusNatureNucleotidesPharmaceutical PreparationsPhase I Clinical TrialsPopulationPositioning AttributeProcessProteinsRNA InterferenceRNA ProcessingRNA VirusesReagentRelative (related person)Replication-Associated ProcessRepliconResearch PersonnelResistanceSystemTestingTherapeuticTimeToxic effectTransgenic MiceTransgenic ModelViralViral hepatitisViremiaVirusVirus DiseasesWestern Worldadeno-associated viral vectoranti-hepatitis Cdesignfusion genein vivointerestliver transplantationmouse modelnovelnovel strategiesoverexpressionpreclinical studyprogramspromoterresponsesmall hairpin RNAsmall moleculesuccesstherapeutic genevector
项目摘要
DESCRIPTION (provided by applicant):
Hepatitis virus infection remains a major health issue throughout the world. Although there are effective drugs and a vaccine for hepatitis B (HBV) infection, there are almost 200,000,000 people infected worldwide. It is estimated that 2 to 4% of Americans are infected with Hepatitis C Virus Infection (HCV), and it is the leading indication for liver transplantation in the western world. For HCV infection, interferon/Ribavarin therapy is expensive, difficult, and not effective in a majority of cases. New small molecule drugs are being developed, but they target a specific protein resulting in the emergence of infectious HCV quasi-species, leading to quick resistance to the therapeutic. RNA interference (RNAi) is a powerful new approach to turning off genes in cells, making it an alternative therapeutic approach to treat infectious processes. Moreover, strategies can be designed to minimize the possibility of escape mutant formation. We have had preliminary success in using a new AAV vector to achieve a safe and sustained >100 times reduction in HBV replication in a transgenic mouse model. Interestingly, we have come across some interesting biological responses to overexpression of shRNA in vivo. Our approach is to develop an RNAi gene therapeutic that would be useful for treating hepatitis virus infection. To do this we will: (1) continue to use a mouse model of HBV to study basic biological responses to shRNA expression in vivo; (2) develop robust shRNA expression sequences against HCV; and (3) test novel AAV shRNA expression cassettes in a bona-fide mouse model of HCV replication in vivo. We believe the data generated during the granting period will develop the reagents necessary to pursue a Phase I clinical trial for HCV infection.
描述(由申请人提供):
肝炎病毒感染仍然是全世界的一个主要健康问题。尽管有针对乙型肝炎 (HBV) 感染的有效药物和疫苗,但全球仍有近 2 亿人感染。据估计,2%至4%的美国人感染丙型肝炎病毒感染(HCV),这是西方世界肝移植的主要适应症。对于 HCV 感染,干扰素/利巴韦林治疗昂贵、困难,并且在大多数情况下无效。新的小分子药物正在开发中,但它们针对特定蛋白质,导致传染性丙型肝炎病毒准种的出现,从而导致对治疗方法的快速耐药。 RNA 干扰 (RNAi) 是一种关闭细胞基因的强大新方法,使其成为治疗感染过程的替代治疗方法。此外,可以设计策略来最大程度地减少逃逸突变体形成的可能性。我们已经初步成功地使用新的 AAV 载体,在转基因小鼠模型中安全、持续地将 HBV 复制减少了 100 倍以上。有趣的是,我们发现了体内 shRNA 过度表达的一些有趣的生物学反应。我们的方法是开发一种可用于治疗肝炎病毒感染的 RNAi 基因疗法。为此,我们将:(1)继续使用HBV小鼠模型来研究体内shRNA表达的基本生物学反应; (2) 开发针对 HCV 的强 shRNA 表达序列; (3) 在 HCV 体内复制的真实小鼠模型中测试新型 AAV shRNA 表达盒。我们相信,在授权期间产生的数据将开发出进行 HCV 感染 I 期临床试验所需的试剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark A Kay其他文献
AAV vectors and tumorigenicity
腺相关病毒载体与致瘤性
- DOI:
10.1038/nbt1007-1111 - 发表时间:
2007-10-01 - 期刊:
- 影响因子:41.700
- 作者:
Mark A Kay - 通讯作者:
Mark A Kay
RNA interference gene therapy: RNA interference gets infectious
RNA干扰基因疗法:RNA干扰具有传染性
- DOI:
10.1038/sj.gt.3302035 - 发表时间:
2003 - 期刊:
- 影响因子:5.1
- 作者:
Ap Mccaffrey;Mark A Kay;Anton P. McCaffrey;Mark A Kay - 通讯作者:
Mark A Kay
Mark A Kay的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark A Kay', 18)}}的其他基金
3' tsRNAs: biologic function and pre-clinical targeting for treating human disease
3 tsRNA:治疗人类疾病的生物学功能和临床前靶向
- 批准号:
10735190 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications
小RNA衍生的tRNA在基因调控中的作用:机制和治疗应用
- 批准号:
9763548 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications
小RNA衍生的tRNA在基因调控中的作用:机制和治疗应用
- 批准号:
9365781 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries
使用复制病毒衣壳文库选择新的 rAAV 载体
- 批准号:
8861132 - 财政年份:2015
- 资助金额:
$ 18.32万 - 项目类别:
AAV capsid engineering for enhancing gene transfer
用于增强基因转移的 AAV 衣壳工程
- 批准号:
10574568 - 财政年份:2015
- 资助金额:
$ 18.32万 - 项目类别:
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries
使用复制病毒衣壳文库选择新的 rAAV 载体
- 批准号:
9022412 - 财政年份:2015
- 资助金额:
$ 18.32万 - 项目类别:
AAV capsid engineering for enhancing gene transfer
用于增强基因转移的 AAV 衣壳工程
- 批准号:
10352396 - 财政年份:2015
- 资助金额:
$ 18.32万 - 项目类别:
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors
衍生新重组 AAV 载体的分子进化策略
- 批准号:
8044028 - 财政年份:2009
- 资助金额:
$ 18.32万 - 项目类别:
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors
衍生新重组 AAV 载体的分子进化策略
- 批准号:
8230691 - 财政年份:2009
- 资助金额:
$ 18.32万 - 项目类别:
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors
衍生新重组 AAV 载体的分子进化策略
- 批准号:
7654164 - 财政年份:2009
- 资助金额:
$ 18.32万 - 项目类别:
相似海外基金
DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
- 批准号:
EP/Y029089/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
- 批准号:
2337776 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
- 批准号:
2338846 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
- 批准号:
2348261 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
- 批准号:
2348346 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
- 批准号:
2348457 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
- 批准号:
2404989 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
- 批准号:
2339310 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
- 批准号:
2339669 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Continuing Grant